|
Market Closed -
Euronext Paris
16:55:00 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8810 EUR | -0.11% |
|
+2.20% | -8.23% |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
| 09-03 | Transgene jumps 20% on positive cancer vaccine data in early trial | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 280M | - | ||||
| 66.93B | |||||
| 61.97B | |||||
| 28.27B | - | ||||
| 24.59B | |||||
| 24.3B | - |
- Stock Market
- Stocks
- TNG Stock
- Charts Transgene
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
